Abstract: The present invention discloses anti-idiotypic antibodies and fragments thereof against inhibitory Factor VIII anti-bodies, said inhibitory antibodies having an affinity for the C2 domain of Factor VIII. The anti-idiotypic antibodies of the present invention are able to completely neutralise in vitro and in an in vivo mouse model the inhibitory activity of FVIII inhibitors. The anti idiotypic antibodies of the present invention can be applied for the prevention, treatment or reduction of bleeding disorders of hemophilia patients with inhibitory antibody against the C2 domain of Factor VIII.
Type:
Grant
Filed:
July 28, 2003
Date of Patent:
September 1, 2009
Assignee:
D. Collen Research Foundation VZW
Inventors:
Jean Guy G. Gilles, Jean-Marie R. Saint-Remy, Marc G. Jacquemin
Abstract: The present invention relates to the treatment of motoneuron diseases. More particularly the invention relates to the treatment of amyotrophic lateral sclerosis (ALS). It is found that the intracerebroventricular delivery of low amounts of vascular endothelial growth factor into a preclinical ALS animal model induces a significant motor performance and prolongation of survival time of said animals.
Type:
Application
Filed:
May 27, 2005
Publication date:
November 13, 2008
Applicants:
Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, D. Collen Research Foundation vzw
Abstract: This invention relates to antagonists of placental growth factor and signalling thereof, pharmaceutical compositions containing such antagonists and the use of such antagonists to prevent bone loss or bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass and/or bone defects in vertebrates, and particularly mammals, including humans.
Type:
Grant
Filed:
June 27, 2003
Date of Patent:
April 15, 2008
Assignees:
D. Collen Research Foundation VZW, K.U. Leuven Research & Development, Vlaams Interuniversitair Instituut Voor Biotechnologie VZW
Inventors:
Peter Carmeliet, Désiré Collen, Roger Bouillon, Gertrudis Carmeliet
Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VII to levels between 40 and 95%. The present invention further disclosed pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.
Abstract: The present invention discloses anti-idiotypic antibodies and fragments thereof against inhibitory Factor VIII anti-bodies, said inhibitory antibodies having an affinity for the C2 domain of Factor VIII. The anti-idiotypic antibodies of the present invention are able to completely neutralise in vitro and in an in vivo mouse model the inhibitory activity of FVIII inhibitors. The anti idiotypic antibodies of the present invention can be applied for the prevention, treatment or reduction of bleeding disorders of hemophilia patients with inhibitory antibody against the C2 domain of Factor VIII.
Type:
Application
Filed:
July 28, 2003
Publication date:
October 26, 2006
Applicant:
D. COLLEN RESEARCH FOUNDATION VZW
Inventors:
Jean Guy Gilles, Jean-Marie Saint-Remy, Marc Jacquemin
Abstract: Described are methods of modulating stem/progenitor cell recruitment involving molecules that agonize the formation of plasmin stimulating the recruitment of stem/progenitor cells, including hematopoietic and endothelial precursor cells. Conversely, antagonists of plasmin can inhibit recruitment of the stem cells. In addition, the identification of the uPA receptor (uPAR) as a retention signal for stem cells in their niche suggests a novel method for increased engraftment and isolation of multipotent stem cells.
Type:
Application
Filed:
March 28, 2006
Publication date:
September 21, 2006
Applicants:
Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, D. Collen Research Foundation vzw
Abstract: The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor for treating, more particularly restoring the function of ischemic tissue, in particular muscles such as myocardium and skeletal muscles.
Abstract: Vascular endothelial growth factor, placenta growth factor or combinations of both including heteodimers are useful in the treatment or prevention of stroke or ischemic diseases in mammals.
Type:
Grant
Filed:
February 5, 2001
Date of Patent:
August 16, 2005
Assignees:
D. Collen Research Foundation vzw, Flanders Interuniversity Institute for Biotechnology, VIB